Zilebesiran Shows Potential in Lowering Blood Pressure in High-Risk Hypertensive Patients
Clinical trial data suggests that zilebesiran, an investigational RNA therapy, may help lower blood pressure in high-risk hypertensive patients, paving the way for new treatment options.
Recent clinical trial results reveal that a single subcutaneous dose of zilebesiran, an investigational RNA interference therapy, has the potential to reduce blood pressure in patients with uncontrolled hypertension and a high risk of cardiovascular disease. The phase II KARDIA-3 trial, conducted across five countries, focused on adult patients with established cardiovascular conditions or high risk factors, who were already on multiple antihypertensive medications but still had elevated blood pressure readings. The study analyzed the effects of zilebesiran at doses of 300 mg and 600 mg compared to placebo, observing changes over a three- to six-month period.
Results indicated a trend toward lower systolic blood pressure (SBP), with patients receiving 300 mg showing a mean reduction of 5 mmHg at three months, although this did not achieve statistical significance. Similar patterns were observed at six months, especially in 24-hour ambulatory blood pressure monitoring, where zilebesiran at both doses lowered SBP by approximately 5 to 7 mmHg compared to placebo. A notable post-hoc analysis showed greater blood pressure reduction in patients already on diuretics and with higher baseline SBP.
Safety assessments demonstrated that most adverse events were mild or moderate and transient, with serious adverse events being rare and comparable across groups. The findings suggest that while the primary endpoints did not reach statistical significance, the data support further investigation of zilebesiran in larger, more definitive phase III trials. As Dr. Neha Pagidipati emphasized, this study provides valuable insights that will inform future research aimed at improving hypertension management and cardiovascular outcomes.
High blood pressure remains a significant contributor to global mortality, and new treatments like zilebesiran could offer more effective options, especially for patients who struggle with achieving blood pressure control using current therapies.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Potential Funding for Gender-Affirming Surgeries Under Medicare Under Review
Australia's independent committee is reviewing whether Medicare should fund gender-affirming surgeries for adults, aiming to improve access and health outcomes for transgender individuals.
Research Shows Sound-Induced Stress Can Intensify and Extend Pain in Mice
New research from Tokyo University of Science uncovers how sound stress alone can heighten and extend pain in mice, highlighting the role of environment in pain perception and inflammation.
Patient-Delivered Care Shows Promise for Sustaining Weight Loss Better Than Traditional Professional Programs
New research suggests that patient-delivered support models may outperform traditional professional programs in sustaining weight loss, offering a sustainable and cost-effective approach to long-term obesity management.
US Ends Use of Vaccine Ingredient Targeted by Anti-Vaccine Movements
The US has decided to end the use of thimerosal, a preservative once targeted by anti-vaccine groups, after scientific reviews confirmed its safety, aiming to improve vaccine confidence.